Hereditary Renal Glycosuria, Diabetes, and Responses to SGLT2 Inhibitor

被引：0
|
作者：
Ren, Qian
Gong, Siqian
Han, Xueyao
Ji, Linong
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-774-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
774-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
    Ren, Qian
    Gong, Siqian
    Han, Xuyao
    Ji, Linong
    JOURNAL OF DIABETES, 2022, 14 (03) : 216 - 220
  • [2] Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
    Bobrowski, David
    Kumar, Reha
    Wu, Peter E.
    Lapointe-Shaw, Lauren
    CLINICAL CASE REPORTS, 2021, 9 (11):
  • [3] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [4] Renal responses to SGLT2 blockade
    Andrea Aguilar
    Nature Reviews Nephrology, 2017, 13 : 320 - 320
  • [5] Renal responses to SGLT2 blockade
    Aguilar, Andrea
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (06) : 320 - 320
  • [6] Beyond Glycosuria: Exploring the intrarenal effects of SGLT2 inhibition in diabetes
    Thomas, M. C.
    Jandeleit-Dahm, K.
    Bonnet, F.
    DIABETES & METABOLISM, 2014, 40 : S17 - S22
  • [7] LUSEOGLIFLOZIN SGLT2 Inhibitor Treatment of Diabetes
    Tiwari, A.
    DRUGS OF THE FUTURE, 2012, 37 (09) : 637 - 643
  • [8] The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor
    Chen, C.
    Lin, Y. C. L. Yi Cheng
    Kao, C. C. K. Chih-Chin
    Huang, C. Y. H. Chun-Yao
    EUROPEAN HEART JOURNAL, 2023, 44
  • [9] Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
    Jackson, Kristen
    Moseley, Kendall F.
    CURRENT OSTEOPOROSIS REPORTS, 2020, 18 (05) : 439 - 448
  • [10] Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
    Kristen Jackson
    Kendall F. Moseley
    Current Osteoporosis Reports, 2020, 18 : 439 - 448
12345